Moleculin Biotech
MBRX
16 hedge funds and large institutions have $1.44M invested in Moleculin Biotech in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
3,160% more capital inflows, than outflows
Capital inflows: $1.4M | Capital outflows: $42.9K
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
4.01% less ownership
Funds ownership: 14.57% → 10.56% (-4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$1.25M |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$94.1K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$17.5K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$15.5K |
| 5 |
LPL Financial
San Diego,
California
|
+$6.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$19.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.2K |
| 3 |
Atticus Wealth Management
Palm Beach Gardens,
Florida
|
-$4.73K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$3.36K |
| 5 |
Kestra Investment Management
Austin,
Texas
|
-$43 |
MBRX Hedge Fund Activity: Q1 2025 in Review
16 of the 7,487 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2025, worth a combined $1.44M — up 82% from $790K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBRX positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $1.25M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $19.5K sold.
- 16 institutional investors held Moleculin Biotech (MBRX) as of Q1 2025, up from 14 in Q4 2024.
- Funds reported $1.44M of Moleculin Biotech stock for Q1 2025, up 82% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q1 2025 and 3 closed out, a net change of +2 holders.
- The largest Moleculin Biotech buyer in Q1 2025 was Armistice Capital, an estimated $1.25M added.
- The largest Moleculin Biotech seller in Q1 2025 was Renaissance Technologies, an estimated $19.5K sold.
Based on aggregated 13F filings for Q1 2025.